AMPLITUDE
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE). Click here to learn more.
C3441021 (TALAPRO2)
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC. Click here to learn more.
MAGNITUDE
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE). Click here to learn more.
PREVALENCE
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer. Click here to learn more.
